Capesaris: Phase II data

Data from 9 men with CRPC maintained on primary androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists alone in the open-label, U.S. Phase II G200707 trial showed that once-daily 2,000 mg oral Capesaris for 15 days did not significantly reduce serum total testosterone levels, but did significantly reduce free testosterone and PSA levels from baseline to day 15. Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando. ...